In short
A clinical trial is underway to investigate the effectiveness of Naloxegol Oxalate, marketed as Moventig, in preventing opioid-induced gastrointestinal motility disturbances in patients with brain injuries. This study, known as the NIPA study, aims to evaluate how Naloxegol administration affects early constipation and ventilator-associated pneumonia in intensive care unit patients receiving opioid medications for pain management.
At a glance
- Study Name
- The NIPA study
- Drug Studied
- Naloxegol Oxalate (Moventig)
- Main Objective
- Evaluate efficacy in preventing early constipation and ventilator-associated pneumonia
- Patient Group
- Brain-injured patients receiving opioid medications in ICU
- Primary Endpoints
- Absence of bowel movements before Day 6 and incidence of VAP before Day 7
- Key Secondary Objectives
- Effects on enteral nutrition tolerance, time to first bowel movement, use of laxatives, late-onset VAP, and neurological prognosis
- Drug Administration
- 25 mg film-coated tablets, oral or via feeding tube
- Study Duration
- Up to 6 months follow-up for neurological prognosis
What is Naloxegol Oxalate?
Naloxegol Oxalate, also known by its brand name Moventig, is a medication used to treat constipation caused by opioid pain medicines in adults with long-lasting pain that is not caused by cancer. It comes in the form of 25 mg film-coated tablets and is taken orally.
Medical Conditions Treated
The clinical trial focuses on using Naloxegol Oxalate to treat two main medical conditions:
- Meningeal hemorrhage: This is bleeding in the protective layers surrounding the brain and spinal cord.
- Gastrointestinal motility disorders: These are conditions that affect the movement of food through the digestive system, often leading to constipation.
How Naloxegol Works
Naloxegol Oxalate belongs to a class of drugs called peripherally acting mu-opioid receptor antagonists. It works by blocking the effects of opioids specifically in the gut, which helps to relieve constipation without interfering with the pain-relieving effects of opioids in the brain.
The NIPA Clinical Trial
The NIPA study (Naloxegol administration to prevent opioids induced gastrointestinal motility disturbance in brain Injured PAtients) is a Phase III clinical trial designed to evaluate the effectiveness of Naloxegol in preventing constipation and other complications in patients with brain injuries who are receiving opioid medications.
Main Objectives of the Trial:
- To evaluate the efficacy of Naloxegol in preventing early constipation (before day 6 of hospitalization).
- To assess its impact on the incidence of early ventilator-associated pneumonia (before day 7 of hospitalization).
Secondary Objectives:
- Assess the effect on tolerance of enteral nutrition (feeding through a tube).
- Evaluate the time to first bowel movement in cases of late constipation.
- Assess the need for rectal laxatives.
- Evaluate the incidence of late-onset ventilator-associated pneumonia.
- Assess the impact on ICU stay and neurological prognosis at 6 months.
- Evaluate the effect on the occurrence of intracranial hypertension (high pressure inside the skull).
Who Can Receive Naloxegol?
The trial has specific criteria for who can participate. Eligible patients typically include:
- Adults admitted to the intensive care unit for head trauma or subarachnoid hemorrhage.
- Patients receiving opioid medications for less than 24 hours.
- Those expected to be on mechanical ventilation for at least 48 hours.
- Patients planned for intracranial pressure monitoring and enteral feeding.
However, there are several conditions that would exclude a patient from receiving Naloxegol, including severe liver disease, kidney failure, gastrointestinal obstruction, and certain other medical conditions or medications.
How Naloxegol is Administered
In the clinical trial, Naloxegol is administered as follows:
- Form: 25 mg film-coated tablets
- Route: Taken orally
- Maximum daily dose: 25 mg
- Maximum total dose: 500 mg
- Maximum treatment period: 20 days
Potential Benefits of Naloxegol
The researchers hope that Naloxegol will provide several benefits for patients with brain injuries who are receiving opioid medications:
- Prevention of constipation
- Reduced risk of ventilator-associated pneumonia
- Improved tolerance of enteral nutrition
- Decreased need for additional laxatives
- Potentially shorter ICU stays and improved neurological outcomes
Precautions and Considerations
While Naloxegol may offer benefits, it's important to be aware of potential risks and considerations:
- It should not be used in patients with known or suspected gastrointestinal obstruction.
- Caution is needed in patients with certain gastrointestinal conditions or recent abdominal injuries.
- It may interact with other medications, particularly those that affect the CYP3A4 enzyme system.
- It's not recommended for use during pregnancy or breastfeeding.
- Patients with severe kidney or liver problems may need dose adjustments or may not be suitable candidates for this medication.